KLONOPIN

Compare KLONOPIN  to:
Compare
Compare

Generic Name for KLONOPIN

Clonazepam 0.5mg+, 1mg, 2mg; tabs; +scored.

Legal Classification:

CIV

Pharmacological Class for KLONOPIN

Benzodiazepine.

Manufacturer of KLONOPIN

Roche Laboratories

Indications for KLONOPIN

Panic disorder.

Adult dose for KLONOPIN

>18yrs: initially 0.25mg twice daily; after 3 days increase to 1mg/day; then may increase every 3 days by 0.125–0.25mg twice daily; max 4mg/day. Wafers: dissolve in mouth; swallow with or without water.

Children's dosing for KLONOPIN

<18yrs: not recommended.

Also:

Contraindications for KLONOPIN

Significant liver disease. Acute narrow-angle glaucoma.

Precautions for KLONOPIN

Suicidal tendencies (monitor). Chronic respiratory disease. Renal impairment. Avoid abrupt cessation. Reevaluate periodically. Monitor blood counts, liver function. Elderly. Labor & delivery, pregnancy (Cat.D), nursing mothers: not recommended.

Interactions for KLONOPIN

Potentiates CNS depression with alcohol, other CNS depressants. Adjust anticonvulsants if needed. Absence seizures with valproate. Caution with drugs that inhibit CYP3A (eg, azole antifungals). Antagonized by CYP450 inducers (eg, phenytoin, carbamazepine, phenobarbital). Wafers may be antagonized by propantheline.

Adverse Reactions for KLONOPIN

CNS effects (esp. depression), hypersalivation, liver disorders, GI upset, blood dyscrasias, paradoxical reactions.

How is KLONOPIN supplied?

Tabs—100
Wafers—60

Related Disease:

Panic disorder

Related Resources

Exel/Exelint infusion set needles recalled

January 26, 2010

FDA notified healthcare professionals of a Class I recall of Exel/Exelint Huber needles, Exel/Exelint Huber Infusion Sets, and Exel/Exelint "Securetouch+" Safety Huber Infusion Sets due to 'coring,' the cutting or dislodging of silicone cores or slivers from the ports into which they are inserted).

Cymbalta approved for maintenance treatment of generalized anxiety disorder (GAD)

November 30, 2009

The FDA has approved Cymbalta (duloxetine HCl, from Lilly) for the maintenance treatment of generalized anxiety disorder (GAD) in adults.

Once-daily venlafaxine extended-release tablets available

August 19, 2009

Osmotica Pharmaceutical and Upstate Pharma, a subsidiary of UCB, have made available venlafaxine extended-release tablets in 37.5mg, 75mg, 150mg, and 225mg dosage strengths.

FDA approves updated labeling for antiepileptic drugs

May 05, 2009

The FDA has approved updated labeling for antiepileptic drugs used to treat epilepsy, psychiatric disorders, and other conditions (eg, migraines, neuropathic pain syndromes).

Neosalus Cream available for dermatitis

March 16, 2010

Quinnova announced the launch of Neosalus Cream, a non-steroidal anti-inflammatory cream for the treatment of various dermatoses (eg, atopic dermatitis, contact dermatitis, and hand eczema).